Formulation: A solid
Formal Name: L-histidyl-2-methylalanyl-L-α-glutamylglycyl-L-seryl-L-phenylalanyl-L-threonyl-L-seryl-L-α-glutamyl-L-leucyl-L-alanyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-N6-[N-(17-carboxy-1-oxoheptadecyl)-L-γ-glutamyl]-L-lysyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-histidyl-L-lysyl-L-isoleucyl-L-threonyl-L-aspartic acid
Purity: ≥98%
Formula Markup: C192H302N46O57 • XNa
Formula Weight: 4166,8
Shelf life (days): 1460
Notes: Dapiglutide is a dual glucagon-like peptide 1 receptor (GLP-1R) and GLP-2R agonist.{69856} It induces cAMP accumulation in HEK293 cells expressing human GLP-1R or GLP-2R (EC50s = 190 and 210 pM, respectively). Dapiglutide (6 nmol/kg) reduces peak blood glucose levels in an oral glucose tolerance test and increases intestinal wet weight in mice. It decreases gastric emptying and increases intestinal weight and length in rats (ED50s = 7.6, 20.7, and 10.7 nmol/kg, respectively). Dapiglutide also promotes body weight recovery, decreases stool water content, and increases intestinal villus height and intestinal length in a mouse model of short bowel and intestinal insufficiency induced by 40% ileocecal resection.